Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1011

1.

Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.

Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W.

Ann Rheum Dis. 2015 Aug 6. pii: annrheumdis-2015-207544. doi: 10.1136/annrheumdis-2015-207544. [Epub ahead of print]

PMID:
26248638
2.

Certolizumab Pegol Remains an Equally Efficacious Treatment of Rheumatoid Arthritis Over a Range of Background Methotrexate Regimens.

Combe B, Furst DE, Keystone EC, van der Heijde D, Luijtens K, Ionescu L, Goel N, Emery P.

Arthritis Care Res (Hoboken). 2015 Aug 3. doi: 10.1002/acr.22676. [Epub ahead of print]

PMID:
26238672
3.

Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O).

Genovese MC, Silverman GJ, Emery P, Gupta RC, Gill A, Veenhuizen M, Xie L, Komocsar WJ, Berclaz PY, Lee C.

J Clin Rheumatol. 2015 Aug;21(5):231-8. doi: 10.1097/RHU.0000000000000276.

PMID:
26203826
4.

A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.

Emery P, Solem C, Majer I, Cappelleri JC, Tarallo M.

Rheumatol Int. 2015 Jul 12. [Epub ahead of print]

PMID:
26164150
5.

Changes in peripheral blood immune cell composition in osteoarthritis.

Ponchel F, Burska AN, Hensor EM, Raja R, Campbell M, Emery P, Conaghan PG.

Osteoarthritis Cartilage. 2015 Jul 8. pii: S1063-4584(15)01227-3. doi: 10.1016/j.joca.2015.06.018. [Epub ahead of print]

6.

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J.

Ann Rheum Dis. 2015 Jul 6. pii: annrheumdis-2015-207588. doi: 10.1136/annrheumdis-2015-207588. [Epub ahead of print]

7.

The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from a Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ranging, Multinational Study.

Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P.

Arthritis Rheumatol. 2015 Jul 2. doi: 10.1002/art.39249. [Epub ahead of print]

PMID:
26138593
8.

Remission in rheumatoid arthritis: is it all the same?

Gul HL, Ferreira JF, Emery P.

Expert Rev Clin Pharmacol. 2015 Sep;8(5):575-86. doi: 10.1586/17512433.2015.1061429. Epub 2015 Jul 3.

PMID:
26131966
9.

The molecular ticks of the Drosophila circadian clock.

Tataroglu O, Emery P.

Curr Opin Insect Sci. 2015 Feb 1;7:51-57.

PMID:
26120561
10.

Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.

Baker JF, Conaghan PG, Emery P, Baker DG, Østergaard M.

Ann Rheum Dis. 2015 Jun 19. pii: annrheumdis-2014-206934. doi: 10.1136/annrheumdis-2014-206934. [Epub ahead of print]

PMID:
26091907
11.

Connecting Circadian Genes to Neurodegenerative Pathways in Fruit Flies.

Emery P.

PLoS Genet. 2015 Jun 11;11(6):e1005266. doi: 10.1371/journal.pgen.1005266. eCollection 2015 Jun. No abstract available.

12.

The prevalence of tenosynovitis of the interosseous tendons of the hand in patients with rheumatoid arthritis.

Rowbotham EL, Freeston JE, Emery P, Grainger AJ.

Eur Radiol. 2015 Jun 5. [Epub ahead of print]

PMID:
26045344
13.

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compán V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA.

Ann Rheum Dis. 2015 May 19. pii: annrheumdis-2015-207526. doi: 10.1136/annrheumdis-2015-207526. [Epub ahead of print]

14.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2015 May 12. pii: annrheumdis-2015-207524. doi: 10.1136/annrheumdis-2015-207524. [Epub ahead of print]

15.

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.

Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P.

Ann Rheum Dis. 2015 Sep;74(9):1734-8. doi: 10.1136/annrheumdis-2014-206496. Epub 2015 Apr 8.

PMID:
25854586
16.

Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.

Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, Goodfield M, Emery P.

Arthritis Rheumatol. 2015 Jun;67(6):1586-91. doi: 10.1002/art.39085.

PMID:
25707733
17.

The OMERACT MRI in Arthritis Working Group - Update on Status and Future Research Priorities.

Østergaard M, Bird P, Gandjbakhch F, Eshed I, Haugen IK, Haavardsholm EA, Lillegraven S, Foltz V, Glinatsi D, Peterfy C, Ejbjerg B, Bøyesen P, Mease PJ, Hermann KG, Emery P, Genant HK, Conaghan PG.

J Rheumatol. 2015 Feb 15. pii: jrheum.141248. [Epub ahead of print]

PMID:
25684771
18.

Etanercept tapering in rheumatoid arthritis.

Emery P, Hammoudeh M, Combe B.

N Engl J Med. 2015 Jan 29;372(5):489-90. doi: 10.1056/NEJMc1414787. No abstract available.

19.

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.

Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH.

BMC Musculoskelet Disord. 2014 Dec 23;15:452. doi: 10.1186/1471-2474-15-452.

20.

Rheumatoid arthritis in 2014: Exciting times for RA research.

Emery P.

Nat Rev Rheumatol. 2015 Feb;11(2):69-70. doi: 10.1038/nrrheum.2014.216. Epub 2014 Dec 23.

PMID:
25536484
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk